Emerging Biomarkers in Personalized Therapy of Lung Cancer
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-319-24932-2_2
Reference115 articles.
1. Cagle PT, Allen TC (2012) Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med 136(12):1482–1491
2. Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology. Arch Pathol Lab Med 137(6):828–860
3. Cagle PT, Sholl LM, Lindeman NI et al (2014) Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. Arch Pathol Lab Med 138(2):171–174
4. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98(12):1817–1824
5. Suda K, Tomizawa K, Mitsudomi T (2010) Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29(1):49–60
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Updates in Pharmacogenetics of Non-Small Cell Lung Cancer;Pharmacogenetics;2021-11-24
2. MicroRNA-1: Diverse role of a small player in multiple cancers;Seminars in Cell & Developmental Biology;2021-05
3. Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics;Advancing Healthcare Through Personalized Medicine;2021
4. Describing the Reportable Range Is Important for Reliable Treatment Decisions;The Journal of Molecular Diagnostics;2018-11
5. Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories;British Journal of Cancer;2018-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3